MAGEA3 and melanoma: In the second study of phase I trials, fifteen participants with the following criteria were enrolled: stage IIIb/IV, HLA-A I+ or HLA-B35+ and HLA-DPO4+ leukocyte phenotype, MAGE-3-overexpressed malignant melanoma (MM) [162].